APR-1051
Advanced Solid Tumors (CCNE1/2, FBXW7, PPP2R1A altered; KRAS G12/13 & TP53 mutant CRC; HPV+ Oropharyngeal, Cervical, Vaginal, Vulvar SCC; Uterine Serous Carcinoma)
Key Facts
About Aprea Therapeutics
Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, selective DNA Damage Response (DDR) inhibitors for cancer. Its strategy leverages the principle of synthetic lethality, aiming to selectively kill cancer cells with specific genetic defects while sparing healthy tissue. The company's near-term value is driven by two clinical-stage assets: APR-1051, a next-generation WEE1 inhibitor, and ATRN-119, a macrocyclic ATR inhibitor, both with key clinical readouts anticipated in 2026. Aprea's mission is to translate foundational academic research into transformative therapies for patients with limited treatment options.
View full company profile